![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/MEDICAMEQ.png)
Share the post "Medicamen Biotech ‘s Q3 2024-25 Latest News: Revenue Dropped by 2.92% YoY"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company’s sales declined by -2.92 % over the year, substantial increase in net sales/revenue by 0.89 %. 🔹 Income over the Year and quarter: There has been decline in other income over the past year which is -83.03 %, Marginal decrease of -51.38% in other income during this quarter. 🔹 Profit over the Year and quarter: Significant improvement in profitability for Medicamen Biotech Limited. Notable increase of 43.94 % in net profit Year to Year, Medicamen Biotech Limited’s profitability increased by 223.23 % in this quarter. 🔹 EPS over the Year and quarter: EPS increased by 43.75 % Year to Year. EPS increased by 223.94 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 46.502 Cr | Rs. 44.743 Cr | Rs. 45.142 Cr | + 0.89 % | -2.92 % |
| Expenses | Rs. 41.61 Cr | Rs. 39.43 Cr | Rs. 38.44 Cr | -2.51 % | -7.62 % |
| Operating Profit | Rs. 4.89 Cr | Rs. 5.31 Cr | Rs. 6.7 Cr | + 26.18 % | + 37.01 % |
| OPM % | 10.52 % | 11.87 % | 14.84 % | + 2.97 % | + 4.32 % |
| Other Income | Rs. 0.831 Cr | Rs. 0.29 Cr | Rs. 0.141 Cr | -51.38 % | -83.03 % |
| Interest | Rs. 0.65 Cr | Rs. 1.04 Cr | Rs. 0.76 Cr | -26.92 % | + 16.92 % |
| Depreciation | Rs. 1.81 Cr | Rs. 2.61 Cr | Rs. 2.21 Cr | -15.33 % | + 22.1 % |
| Profit before tax | Rs. 3.26 Cr | Rs. 1.95 Cr | Rs. 3.87 Cr | + 98.46 % | + 18.71 % |
| Tax % | 37.96 % | 53.83 % | 24.63 % | -29.2 % | -13.33 % |
| Net Profit | Rs. 2.03 Cr | Rs. 0.9 Cr | Rs. 2.92 Cr | + 224.44 % | + 43.84 % |
| EPS in Rs | Rs. 1.6 | Rs. 0.71 | Rs. 2.3 | + 223.94 % | + 43.75 % |
Today, we’re looking at Medicamen Biotech Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a significant year-over-year sales decline of -2.92 %. However, it did see a marginal increase of 0.89 % from the previous quarter. Expenses decreased slightly by -2.51 % quarter-on-quarter, aligning with the annual decline of -7.62 %. Operating profit, while up 37.01 % compared to last year, faced a quarter-on-quarter increase of 26.18 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 4.32 %, but an expansion of 2.97 % sequentially. Other income fell by -51.38 % compared to the last quarter, despite an annual decline of -83.03 %. Interest expenses dropped significantly by -26.92 % from the previous quarter, yet the year-over-year increase remains at a moderate 16.92 %. Depreciation costs fell by -15.33 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 22.1 %. Profit before tax grew annually by 18.71 % but saw an increase from the preceding quarter by 98.46 %.
Tax expenses as a percentage of profits decreased slightly by -13.33 % compared to last year, with a more notable quarter-on-quarter decrease of -29.2 %. Net profit rose by 43.84 % year-on-year but experienced a 224.44 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 43.75 % but a quarterly rise of 223.94 %. In summary, Medicamen Biotech Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 46.502 Cr | Rs. 44.743 Cr | Rs. 45.142 Cr | + 0.89 % | -2.92 % |
| Expenses | Rs. 41.61 Cr | Rs. 39.43 Cr | Rs. 38.44 Cr | -2.51 % | -7.62 % |
| Operating Profit | Rs. 4.89 Cr | Rs. 5.31 Cr | Rs. 6.7 Cr | + 26.18 % | + 37.01 % |
| Net Profit | Rs. 2.03 Cr | Rs. 0.9 Cr | Rs. 2.92 Cr | + 224.44 % | + 43.84 % |
| EPS in Rs | Rs. 1.6 | Rs. 0.71 | Rs. 2.3 | + 223.94 % | + 43.75 % |
In reviewing Medicamen Biotech Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -2.92 % year-on-year, however, there was a minor increase of 0.89 % from the previous quarter. Expenses decreased by -7.62 % compared to the previous year, with a decrease of -2.51 % quarter-on-quarter. Operating Profit surged by 37.01 % annually, and saw a 26.18 % increase from the last quarter.
Net Profit showed yearly increase of 43.84 %, and experienced a 224.44 % increase from the previous quarter. Earnings Per Share (EPS) rose by 43.75 % annually, however rose by 223.94 % compared to the last quarter. In essence, while Medicamen Biotech Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/shareholding/6584c1a376ed26f37a120d2f_mural-blog-images (16) (2).jpg)
